Aralez Bio key facts
- Developer of noncanonical amino acids designed to make products sustainably.
- Aralez Bio’s last known valuation is $40.5M.
- It has raised $24.0M; the latest was Later Stage VC ($12.0M) in Dec 2024.
- Notable investors include Climate Capital, Activate Global, Fifty Years, Good Growth Capital, Impact Science Ventures — 13 tracked in total.
- Status: Privately Held (backing).
Who backs Aralez Bio
13+- ·The complete investor list: 13 names
- ·Watch Aralez Bio: the Monday email on marks, rounds and moves
Aralez Bio funding rounds
No funding rounds for Aralez Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Aralez Bio valuation
Aralez Bio's last known valuation is $40.5 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Aralez Bio investors
13 investors are on record for Aralez Bio, including Climate Capital, Activate Global, Fifty Years and Good Growth Capital. By type, the record holds 5 venture capital firms.
About Aralez Bio
Developer of noncanonical amino acids designed to make products sustainably. The company specializes in inventing an enzymatic method for synthesizing noncanonical amino acids (NCAA) also called unusual or unnatural amino acids and the proprietary approach allows NCAA to be synthesized with enantiopurity in a single step, enabling clients to access amino acids that are needed for innovations in pharmaceuticals, agriculture, and functional materials.
- Sector
- Healthcare
- HQ
- San Leandro, CA, United States
- Founded
- 2019
- Employees
- 34
- Website
- aralezbio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Aralez Bio’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.